Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

AIMS: Liraglutide, a GLP‐1 receptor agonist, regulates appetite via receptors in the brain. Because of concerns regarding the potential of centrally‐acting anti‐obesity medications to affect mental health, pooled neuropsychiatric safety data from all phase 2 and 3a randomized, double‐blind trials wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: O'Neil, Patrick M., Aroda, Vanita R., Astrup, Arne, Kushner, Robert, Lau, David C. W., Wadden, Thomas A., Brett, Jason, Cancino, Ana‐Paula, Wilding, John P. H.
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655710/
https://ncbi.nlm.nih.gov/pubmed/28386912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12963
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados